Oxford Biomedica PLC Total Voting Rights (2319T)

TIDMOXB

RNS Number : 2319T

Oxford Biomedica PLC

02 July 2018

Oxford BioMedica

Total Voting Rights

Oxford, UK - 2 July 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), announces that in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital as at the close of business on 29 June 2018 consisted of 65,718,929 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

Accordingly, the total number of voting rights in Oxford BioMedica plc at the date of this notice is 65,718,929.

The above figure (65,718,929) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford BioMedica plc under the FCA's Disclosure and Transparency Rules.

- Ends -

 
 For further information, please contact: 
  Oxford BioMedica plc:                       Tel: [phone] 
   John Dawson, Chief Executive Officer        783 000 
   Stuart Paynter, Chief Financial Officer 
  Consilium Strategic Communications          Tel: +44 (0)20 
   Mary-Jane Elliott/Matthew Neal/             3709 5700 
   Oliver Manser/Laura Thornton 
 

Notes for editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R)), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

TVREAPXAELKPEEF

(END) Dow Jones Newswires

July 02, 2018 04:47 ET (08:47 GMT)